| 苏敬蔚,苏志雄,陈二宝,柯裕民,吴 疆.参芪扶正注射液联合顺铂和培美曲塞对晚期非小细胞肺癌患者肿瘤标志物、Th1/Th2细胞因子和血清miR-29b、miR-221的影响[J].,2024,(11):2115-2119 |
| 参芪扶正注射液联合顺铂和培美曲塞对晚期非小细胞肺癌患者肿瘤标志物、Th1/Th2细胞因子和血清miR-29b、miR-221的影响 |
| Effects of Shenqi Fuzheng Injection Combined with Cisplatin and Pemetrexed on Tumor Markers, Th1/Th2 Cytokines, and Serum miR-29b and miR-221 in Patients with Advanced Non-Small Cell Lung Cancer |
| 投稿时间：2024-02-08 修订日期：2024-02-27 |
| DOI：10.13241/j.cnki.pmb.2024.11.021 |
| 中文关键词: 晚期非小细胞肺癌 参芪扶正注射液 顺铂 培美曲塞 肿瘤标志物 Th1/Th2细胞因子 miR-29b miR-221 |
| 英文关键词: Advanced non-small cell lung cancer Shenqi Fuzheng Injection Cisplatin Pemetrexed Tumor markers Th1/Th2 cytokines miR-29b miR-221 |
| 基金项目:青海省2023年第一批中央引导地方科技发展资金计划项目（2023ZY016） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 1 |
| 中文摘要: |
| 摘要 目的：探讨参芪扶正注射液联合顺铂和培美曲塞对晚期非小细胞肺癌（NSCLC）患者肿瘤标志物、辅助性T细胞（Th）1/Th2细胞因子和血清微小核糖核酸（miR）-29b、miR-221的影响。方法：按照随机数字表法将福建省立医院2020年3月~2022年12月收治的131例晚期NSCLC患者分为对照组（顺铂和培美曲塞治疗，n=65）和研究组（参芪扶正注射液联合顺铂和培美曲塞治疗，n=66）。对比两组疗效、肿瘤标志物水平、Th1/Th2细胞因子、血清miR-29b、miR-221表达水平，并观察两组不良反应发生率。结果：研究组的客观缓解率（48.48%）、疾病控制率（81.82%）高于对照组（29.23%）、（60.00%）（P<0.05）。研究组治疗后癌胚抗原（CEA）、细胞角质蛋白19片段（CYFRA21-1）、Th2、白细胞介素-4（IL-4）、鳞状上皮细胞癌抗原（SCC-Ag）、miR-221低于对照组（P<0.05）。研究组治疗后γ-干扰素（IFN-γ）、Th1、miR-29b高于对照组（P<0.05）。两组间不良反应发生比较无差异（P>0.05）。结论：与单纯化疗相比，结合参芪扶正注射液治疗晚期NSCLC患者，可有效降低肿瘤标志物水平，提高临床疗效，考虑可能与改善免疫功能和调节血清miR-29b、miR-221表达水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of shenqi fuzheng injection combined with cisplatin and pemetrexed on tumor markers, helper T cell (Th) 1/Th2 cytokines and serum microRNA (miR)-29b and miR-221 in patients with advanced non-small cell lung cancer (NSCLC). Methods: 131 patients with advanced NSCLC who were admitted to Fujian Provincial Hospital from March 2020 to December 2022 were divided into control group (cisplatin and pemetrexed treatment, n=65) and study group (shenqi fuzheng injection combined with cisplatin and pemetrexed treatment, n=66) according to the random number table method. The efficacy, tumor marker levels, Th1/Th2 cytokines, serum miR-29b and miR-221 expression levels were compared between two groups, and the incidence of adverse reactions was observed. Results: The objective remission rate (48.48%) and disease control rate (81.82%) in study group were higher than those in control group (29.23%) and (60.00%) (P<0.05). After treatment, carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), Th2, interleukin-4 (IL-4), squamous cell carcinoma antigen (SCC-Ag) and miR-221 in study group were lower than those in control group (P<0.05). After treatment, γ-interferon (IFN-γ), Th1 and miR-29b in study group were higher than those in control group (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Compare with chemotherapy alone, shenqi fuzheng injection can effectively reduce the level of tumor markers and improve the clinical efficacy in the treatment of advanced NSCLC patients, which may be relate to the improvement of immune function and the regulation of serum miR-29b and miR-221 expression levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
